Avalo Therapeutics, Inc.
AVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534120
In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Avalo Therapeutics, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 28 | 12 | −16 |
| Shares | 1.34M | 23.0K | −1.32M (−98.3%) |
| Value | $158.9K | $209.4K | +$50.4K (+31.7%) |
New holders (3)
Institutions that held Avalo Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Natixis | 4,604 | $43.3K | 0.00% |
| FNY Investment Advisers, LLC | 522 | $4.00K | 0.00% |
| JPMorgan Chase & Co | 2 | $18 | 0.00% |
Sold out (19)
Institutions that held Avalo Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Acadian Asset Management LLC | 283,306 | $34.0K |
| Virtu Financial LLC | 185,345 | $22.0K |
| Baader Bank INC | 184,373 | $19.8K |
| Geode Capital Management, LLC | 133,518 | $16.1K |
| Vanguard Group Inc | 91,817 | $11.1K |
| Banque Cantonale Vaudoise | 81,000 | $10.0K |
| JustInvest LLC | 37,358 | $4.51K |
| Level Four Advisory Services, LLC | 36,153 | $4.36K |
| Jane Street Group, LLC | 27,482 | $3.32K |
| State Street Corp | 25,643 | $3.10K |
| Susquehanna International Group, LLP | 22,714 | $2.74K |
| Mariner, LLC | 18,582 | $2.24K |
| XTX Topco Ltd | 18,498 | $2.23K |
| Two Sigma Securities, LLC | 15,601 | $1.88K |
| Northern Trust Corp | 10,836 | $1.31K |
| Fifth Third Bancorp | 279 | $34 |
| Meeder Asset Management Inc | 62 | $7 |
| Newbridge Financial Services Group, Inc. | 10 | $1 |
| Parallel Advisors, LLC | 1 | $0 |